FiercePharmaOriginal article
{"a":[{"_":"Teva scores rare partial win in CMS price negotiation appeal","$":{"href":"/pharma/teva-scores-rare-partial-court-win-vs-cms-price-negotiations","hreflang":"en"}}]}
RegulatoryMixedPositive
AI Analysis
Summary
Teva Pharmaceuticals secured a partial legal victory when the U.S. Court of Appeals for Washington, D.C. remanded a previous ruling back to lower court for further review in its challenge to CMS price negotiation procedures under the IRA.
Outcome Details
U.S. Court of Appeals for Washington, D.C. sent previous ruling back to lower court for further review regarding CMS determination of 'bona fide marketing' for generic or biosimilar drugs
Importance:6/10
Sentiment:
0.30
regulatorylegalprice negotiationIRAgeneric drugsbiosimilarscourt ruling
Related Companies
Read the original article
Published by FiercePharma on August 18, 2026 5:09 PM